Mechanisms of endocrine therapy-responsive and -unresponsive prostate tumours.
暂无分享,去创建一个
[1] 隆 勝田,et al. 卵巣がんにおける予後予測マーカーとしての血中heparin binding epidermal growth factor-like growth factorの意義 , 2005 .
[2] D. Ghosh,et al. Androgen-Independent Prostate Cancer Is a Heterogeneous Group of Diseases , 2004, Cancer Research.
[3] Georg Bartsch,et al. The androgen receptor co‐activator CBP is up‐regulated following androgen withdrawal and is highly expressed in advanced prostate cancer , 2004, The Journal of pathology.
[4] J. Ni,et al. Functional Domain and Motif Analyses of Androgen Receptor Coregulator ARA70 and Its Differential Expression in Prostate Cancer* , 2004, Journal of Biological Chemistry.
[5] J. Reel,et al. Steroid hormonal regulation of growth, prostate specific antigen secretion, and transcription mediated by the mutated androgen receptor in CWR22Rv1 human prostate carcinoma cells , 2004, Molecular and Cellular Endocrinology.
[6] G. Bartsch,et al. Prostate cancer cells generated during intermittent androgen ablation acquire a growth advantage and exhibit changes in epidermal growth factor receptor expression , 2004, The Prostate.
[7] S. Taneja,et al. ART-27, an Androgen Receptor Coactivator Regulated in Prostate Development and Cancer* , 2004, Journal of Biological Chemistry.
[8] C. Heinlein,et al. Androgen receptor in prostate cancer. , 2004, Endocrine reviews.
[9] H. Kung,et al. Interleukin-8 confers androgen-independent growth and migration of LNCaP: differential effects of tyrosine kinases Src and FAK , 2004, Oncogene.
[10] F. S. French,et al. Epidermal Growth Factor Increases Coactivation of the Androgen Receptor in Recurrent Prostate Cancer* , 2004, Journal of Biological Chemistry.
[11] S. Kulp,et al. 3-Phosphoinositide-Dependent Protein Kinase-1/Akt Signaling Represents a Major Cyclooxygenase-2-Independent Target for Celecoxib in Prostate Cancer Cells , 2004, Cancer Research.
[12] T. Tammela,et al. Expression of Androgen Receptor Coregulators in Prostate Cancer , 2004, Clinical Cancer Research.
[13] V. Adhami,et al. Modulation of phosphatidylinositol‐3‐kinase/protein kinase B‐ and mitogen‐activated protein kinase‐pathways by tea polyphenols in human prostate cancer cells , 2004, Journal of cellular biochemistry.
[14] Desok Kim,et al. The Androgen Axis in Recurrent Prostate Cancer , 2004, Clinical Cancer Research.
[15] H. Fujita,et al. The Adrenal Androgen Androstenediol Is Present in Prostate Cancer Tissue after Androgen Deprivation Therapy and Activates Mutated Androgen Receptor , 2004, Cancer Research.
[16] C. Ip,et al. Prostate Specific Antigen Expression Is Down-Regulated by Selenium through Disruption of Androgen Receptor Signaling , 2004, Cancer Research.
[17] M. Ricote,et al. Immunohistochemical analysis of the IL‐6 family of cytokines and their receptors in benign, hyperplasic, and malignant human prostate , 2004, The Journal of pathology.
[18] Chawnshang Chang,et al. Suppression Versus Induction of Androgen Receptor Functions by the Phosphatidylinositol 3-Kinase/Akt Pathway in Prostate Cancer LNCaP Cells with Different Passage Numbers* , 2003, Journal of Biological Chemistry.
[19] M. Fornaro,et al. Fibronectin Protects Prostate Cancer Cells from Tumor Necrosis Factor-α-induced Apoptosis via the AKT/Survivin Pathway* , 2003, Journal of Biological Chemistry.
[20] P. Koivisto,et al. Androgen Receptor Mutations in High-Grade Prostate Cancer before Hormonal Therapy , 2003, Laboratory Investigation.
[21] Ming-Shyue Lee,et al. ERK inhibitor PD98059 enhances docetaxel‐induced apoptosis of androgen‐independent human prostate cancer cells , 2003, International journal of cancer.
[22] M. Tsai,et al. Role of the Steroid Receptor Coactivator SRC-3 in Cell Growth , 2003, Molecular and Cellular Biology.
[23] G. Piazza,et al. Exisulind and related compounds inhibit expression and function of the androgen receptor in human prostate cancer cells. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[24] S. Oñate,et al. Interleukin-4 enhances prostate-specific antigen expression by activation of the androgen receptor and Akt pathway , 2003, Oncogene.
[25] M. Yamaoka,et al. Enhanced androgen receptor signaling correlates with the androgen-refractory growth in a newly established MDA PCa 2b-hr human prostate cancer cell subline. , 2003, Cancer research.
[26] Hong-Chiang Chang,et al. Modulation of androgen receptor transactivation by gelsolin: a newly identified androgen receptor coregulator. , 2003, Cancer research.
[27] K. Knudsen,et al. Specificity of cyclin D1 for androgen receptor regulation. , 2003, Cancer research.
[28] K. Grigor,et al. Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer , 2003, British Journal of Cancer.
[29] P. Kantoff,et al. Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] Kyucheol Cho,et al. Transforming growth factor-β1 activates interleukin-6 expression in prostate cancer cells through the synergistic collaboration of the Smad2, p38-NF-κB, JNK, and Ras signaling pathways , 2003, Oncogene.
[31] J. Simons,et al. Androgens stimulate hypoxia-inducible factor 1 activation via autocrine loop of tyrosine kinase receptor/phosphatidylinositol 3'-kinase/protein kinase B in prostate cancer cells. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[32] Chawnshang Chang,et al. Interleukin-6 differentially regulates androgen receptor transactivation via PI3K-Akt, STAT3, and MAPK, three distinct signal pathways in prostate cancer cells. , 2003, Biochemical and biophysical research communications.
[33] S. Yeh,et al. Reducing the Agonist Activity of Antiandrogens by a Dominant-negative Androgen Receptor Coregulator ARA70 in Prostate Cancer Cells* , 2003, Journal of Biological Chemistry.
[34] T. Libermann,et al. Constitutive activation of nuclear factor kappaB p50/p65 and Fra-1 and JunD is essential for deregulated interleukin 6 expression in prostate cancer. , 2003, Cancer research.
[35] J. Thrasher,et al. Androgen stimulates matrix metalloproteinase-2 expression in human prostate cancer. , 2003, Endocrinology.
[36] D. Neal,et al. Expression of Tip60, an androgen receptor coactivator, and its role in prostate cancer development , 2003, Oncogene.
[37] E. Bissonette,et al. Attenuation of Ras signaling restores androgen sensitivity to hormone-refractory C4-2 prostate cancer cells. , 2003, Cancer research.
[38] Gaofeng Wang,et al. Requirement for direct cross-talk between B1 and B2 kinin receptors for the proliferation of androgen-insensitive prostate cancer PC3 cells. , 2003, The Biochemical journal.
[39] E. Bissonette,et al. Constitutive activation of the Ras/mitogen-activated protein kinase signaling pathway promotes androgen hypersensitivity in LNCaP prostate cancer cells. , 2003, Cancer research.
[40] R. Agarwal,et al. Grape seed extract inhibits EGF-induced and constitutively active mitogenic signaling but activates JNK in human prostate carcinoma DU145 cells: possible role in antiproliferation and apoptosis , 2003, Oncogene.
[41] J. C. Ghosh,et al. Regulation of Androgen Receptor Activity by the Nuclear Receptor Corepressor SMRT* , 2003, The Journal of Biological Chemistry.
[42] M. Tsai,et al. Overexpression of Cdc25B, an androgen receptor coactivator, in prostate cancer , 2003, Oncogene.
[43] D. Fuchs,et al. Accelerated in vivo growth of prostate tumors that up-regulate interleukin-6 is associated with reduced retinoblastoma protein expression and activation of the mitogen-activated protein kinase pathway. , 2003, The American journal of pathology.
[44] G. Jenster,et al. AKT-Independent Protection of Prostate Cancer Cells from Apoptosis Mediated through Complex Formation between the Androgen Receptor and FKHR , 2003, Molecular and Cellular Biology.
[45] C. Sultan,et al. Molecular action of androgens , 2002, Molecular and Cellular Endocrinology.
[46] S. Tsao,et al. Activation of MAPK signaling pathway is essential for Id-1 induced serum independent prostate cancer cell growth , 2002, Oncogene.
[47] G. Buchanan,et al. A novel androgen receptor mutant, A748T, exhibits hormone concentration-dependent defects in nuclear accumulation and activity despite normal hormone-binding affinity. , 2002, Molecular endocrinology.
[48] C. Tepper,et al. Characterization of a novel androgen receptor mutation in a relapsed CWR22 prostate cancer xenograft and cell line. , 2002, Cancer research.
[49] J. Pow-Sang,et al. Constitutive activation of Stat3 in human prostate tumors and cell lines: direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cells. , 2002, Cancer research.
[50] M. Vihinen,et al. Pattern of Somatic Androgen Receptor Gene Mutations in Patients with Hormone-Refractory Prostate Cancer , 2002, Laboratory Investigation.
[51] E. Messing,et al. Activation of mitogen-activated protein kinase pathway by the antiandrogen hydroxyflutamide in androgen receptor-negative prostate cancer cells. , 2002, Cancer research.
[52] D. Tindall,et al. p300 mediates androgen-independent transactivation of the androgen receptor by interleukin 6. , 2002, Cancer research.
[53] Nicholas Bruchovsky,et al. Ligand-independent Activation of the Androgen Receptor by Interleukin-6 and the Role of Steroid Receptor Coactivator-1 in Prostate Cancer Cells* , 2002, The Journal of Biological Chemistry.
[54] Xin Yu,et al. Heterogeneous expression and functions of androgen receptor co-factors in primary prostate cancer. , 2002, The American journal of pathology.
[55] L. Morel,et al. Androgen receptor expression is regulated by the phosphoinositide 3-kinase/Akt pathway in normal and tumoral epithelial cells. , 2002, The Biochemical journal.
[56] G. Bartsch,et al. Acquisition of agonistic properties of nonsteroidal antiandrogens after treatment with oncostatin M in prostate cancer cells. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[57] M. Gershengorn,et al. Synergistic activation of the androgen receptor by bombesin and low-dose androgen. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[58] E. Messing,et al. Vitamin E succinate inhibits the function of androgen receptor and the expression of prostate-specific antigen in prostate cancer cells , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[59] C. Cordon-Cardo,et al. 17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[60] Liang Xia,et al. Functional analysis of 44 mutant androgen receptors from human prostate cancer. , 2002, Cancer research.
[61] D. Tindall,et al. Disruption of androgen receptor function inhibits proliferation of androgen-refractory prostate cancer cells. , 2002, Cancer research.
[62] J. Swinnen,et al. Role of the phosphatidylinositol 3'-kinase/PTEN/Akt kinase pathway in the overexpression of fatty acid synthase in LNCaP prostate cancer cells. , 2002, Cancer research.
[63] P. Walther,et al. Glucocorticoids manifest androgenic activity in a cell line derived from a metastatic prostate cancer. , 2001, Cancer research.
[64] D. Neal,et al. Expression of RAC 3, a steroid hormone receptor co-activator in prostate cancer , 2001, British Journal of Cancer.
[65] H. Kung,et al. Neuropeptide-Induced Androgen Independence in Prostate Cancer Cells: Roles of Nonreceptor Tyrosine Kinases Etk/Bmx, Src, and Focal Adhesion Kinase , 2001, Molecular and Cellular Biology.
[66] M. Ittmann,et al. Interleukin-6 is an autocrine growth factor in human prostate cancer. , 2001, The American journal of pathology.
[67] P. Koivisto,et al. Androgen Receptor Alterations in Prostate Cancer Relapsed during a Combined Androgen Blockade by Orchiectomy and Bicalutamide , 2001, Laboratory Investigation.
[68] D. Tindall,et al. Role of PI3K signaling in survival and progression of LNCaP prostate cancer cells to the androgen refractory state. , 2001, Endocrinology.
[69] L. Ossowski,et al. Overexpressed androgen receptor linked to p21WAF1 silencing may be responsible for androgen independence and resistance to apoptosis of a prostate cancer cell line. , 2001, Cancer research.
[70] G. Prins,et al. Androgen receptor mediates the reduced tumor growth, enhanced androgen responsiveness, and selected target gene transactivation in a human prostate cancer cell line. , 2001, Cancer research.
[71] R. K Srivastava,et al. Constitutively active Akt is an important regulator of TRAIL sensitivity in prostate cancer , 2001, Oncogene.
[72] H. Klocker,et al. Prostate cancer cells (LNCaP) generated after long-term interleukin 6 (IL-6) treatment express IL-6 and acquire an IL-6 partially resistant phenotype. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[73] K. Kakudo,et al. Phosphorylation of mitogen-activated protein kinase is inhibited by calcitonin in DU145 prostate cancer cells. , 2001, Cancer research.
[74] F. S. French,et al. A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. , 2001, Cancer research.
[75] R L Vessella,et al. Advances in Brief Amplification and Overexpression of Androgen Receptor Gene in Hormone-Refractory Prostate Cancer 1 , 2001 .
[76] J. Richie,et al. Caveolin-1 Interacts with Androgen Receptor , 2001, The Journal of Biological Chemistry.
[77] F. S. French,et al. Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. , 2001, Cancer research.
[78] Y. Chen,et al. Quercetin inhibits the expression and function of the androgen receptor in LNCaP prostate cancer cells. , 2001, Carcinogenesis.
[79] K. Makino,et al. HER-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway. , 2000, Cancer research.
[80] T. Tammela,et al. Androgen receptor gene amplification at primary progression predicts response to combined androgen blockade as second line therapy for advanced prostate cancer. , 2000, The Journal of urology.
[81] M. Toyota,et al. Epigenetic Regulation of Androgen Receptor Gene Expression in Human Prostate Cancers , 2000, Laboratory Investigation.
[82] D. Edwards,et al. Erratum: A c619y mutation in the human androgen receptor causes inactivation and mislocalization of the receptor with concomitant sequestration of SRC-1 (steroid receptor coactivator 1) (Molecular Endocrinology (1999) 13 (2065-2075)) , 2000 .
[83] A. Bilancio,et al. Steroid‐induced androgen receptor–oestradiol receptor β–Src complex triggers prostate cancer cell proliferation , 2000, The EMBO journal.
[84] M. Gleave,et al. Ligand-independent activation of the androgen receptor by the differentiation agent butyrate in human prostate cancer cells. , 2000, Cancer research.
[85] S. Yeh,et al. Increase of androgen-induced cell death and androgen receptor transactivation by BRCA1 in prostate cancer cells. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[86] S. Kato,et al. Cyclin E as a Coactivator of the Androgen Receptor , 2000, The Journal of cell biology.
[87] R. Vessella,et al. Increased AKT Activity Contributes to Prostate Cancer Progression by Dramatically Accelerating Prostate Tumor Growth and Diminishing p27Kip1 Expression* , 2000, The Journal of Biological Chemistry.
[88] H. Klocker,et al. Inhibition of LNCaP prostate cancer cells by means of androgen receptor antisense oligonucleotides , 2000, Cancer Gene Therapy.
[89] Donna M. Peehl,et al. Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor , 2000, Nature Medicine.
[90] M. Gleave,et al. Overexpression of insulin-like growth factor binding protein-5 helps accelerate progression to androgen-independence in the human prostate LNCaP tumor model through activation of phosphatidylinositol 3'-kinase pathway. , 2000, Endocrinology.
[91] S. Chi,et al. Mitogenic conversion of transforming growth factor-beta1 effect by oncogenic Ha-Ras-induced activation of the mitogen-activated protein kinase signaling pathway in human prostate cancer. , 2000, Cancer research.
[92] K. R. Ely,et al. Ligand responsiveness in human prostate cancer: structural analysis of mutant androgen receptors from LNCaP and CWR22 tumors. , 2000, Cancer research.
[93] W. Farrar,et al. Interleukin 6 activates androgen receptor-mediated gene expression through a signal transducer and activator of transcription 3-dependent pathway in LNCaP prostate cancer cells. , 2000, Cancer research.
[94] T. Chung,et al. STAT3 mediates IL‐6‐induced growth inhibition in the human prostate cancer cell line LNCaP , 2000, The Prostate.
[95] H. Klocker,et al. Androgen receptor protein is down-regulated by basic fibroblast growth factor in prostate cancer cells , 1999, British Journal of Cancer.
[96] D. Peehl,et al. Two mutations identified in the androgen receptor of the new human prostate cancer cell line MDA PCa 2a. , 1999, The Journal of urology.
[97] D. Edwards,et al. A C619Y mutation in the human androgen receptor causes inactivation and mislocalization of the receptor with concomitant sequestration of SRC-1 (steroid receptor coactivator 1) , 1999, Molecular endocrinology.
[98] C. Cordon-Cardo,et al. Prostate cancer cell cycle regulators: response to androgen withdrawal and development of androgen independence. , 1999, Journal of the National Cancer Institute.
[99] C. Young,et al. A nonsteroidal anti-inflammatory drug, flufenamic acid, inhibits the expression of the androgen receptor in LNCaP cells. , 1999, Endocrinology.
[100] M. Loda,et al. Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. , 1999, Cancer research.
[101] Martin R. Schneider,et al. Switch from antagonist to agonist of the androgen receptor blocker bicalutamide is associated with prostate tumour progression in a new model system , 1999, British Journal of Cancer.
[102] L. Ossowski,et al. Activation of Rb and decline in androgen receptor protein precede retinoic acid–induced apoptosis in androgen‐dependent LNCaP cells and their androgen‐independent derivative , 1999, Journal of cellular physiology.
[103] E. Small,et al. Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. , 1999, Cancer research.
[104] S. Yeh,et al. From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[105] G. Kulik,et al. Antiapoptotic signaling in LNCaP prostate cancer cells: a survival signaling pathway independent of phosphatidylinositol 3'-kinase and Akt/protein kinase B. , 1999, Cancer research.
[106] S. Yeh,et al. Cloning and Characterization of Human Prostate Coactivator ARA54, a Novel Protein That Associates with the Androgen Receptor* , 1999, The Journal of Biological Chemistry.
[107] S. Inui,et al. Cloning and Characterization of Androgen Receptor Coactivator, ARA55, in Human Prostate* , 1999, The Journal of Biological Chemistry.
[108] Noah Craft,et al. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase , 1999, Nature Medicine.
[109] B. Bonavida,et al. Oncostatin M (OM) promotes the growth of DU 145 human prostate cancer cells, but not PC-3 or LNCaP, through the signaling of the OM specific receptor. , 1999, Anticancer research.
[110] H. Frierson,et al. Activation of mitogen-activated protein kinase associated with prostate cancer progression. , 1999, Cancer research.
[111] Desok Kim,et al. Androgen receptor expression in androgen-independent prostate cancer is associated with increased expression of androgen-regulated genes. , 1998, Cancer research.
[112] J. Herman,et al. Methylation of the androgen receptor promoter CpG island is associated with loss of androgen receptor expression in prostate cancer cells. , 1998, Cancer research.
[113] H. Klocker,et al. Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor. , 1998, Cancer research.
[114] H. Klocker,et al. Interleukin 1beta mediates the modulatory effects of monocytes on LNCaP human prostate cancer cells. , 1998, British Journal of Cancer.
[115] S. Yeh,et al. Retinoblastoma, a tumor suppressor, is a coactivator for the androgen receptor in human prostate cancer DU145 cells. , 1998, Biochemical and biophysical research communications.
[116] G. Wilding,et al. Promotion of agonist activity of antiandrogens by the androgen receptor coactivator, ARA70, in human prostate cancer DU145 cells. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[117] K. Hamil,et al. Dehydroepiandrosterone activates mutant androgen receptors expressed in the androgen-dependent human prostate cancer xenograft CWR22 and LNCaP cells. , 1997, Molecular endocrinology.
[118] J. Trachtenberg,et al. Androgen-dependent cell cycle arrest and apoptotic death in PC-3 prostatic cell cultures expressing a full-length human androgen receptor , 1997, Molecular and Cellular Endocrinology.
[119] O. Jänne,et al. Effects of mitogens on androgen receptor-mediated transactivation. , 1996, Endocrinology.
[120] Barrack Er. Androgen receptor mutations in prostate cancer. , 1996 .
[121] L. Nazareth,et al. Activation of the Human Androgen Receptor through a Protein Kinase A Signaling Pathway* , 1996, The Journal of Biological Chemistry.
[122] H. Klocker,et al. Androgen receptor status of lymph node metastases from prostate cancer , 1996, The Prostate.
[123] H. Klocker,et al. Mutant androgen receptors in prostatic tumors distinguish between amino‐acid‐sequence requirements for transactivation and ligand binding , 1995, International journal of cancer.
[124] H. Klocker,et al. Distant metastases from prostatic carcinoma express androgen receptor protein. , 1995, Cancer research.
[125] Jorma Isola,et al. In vivo amplification of the androgen receptor gene and progression of human prostate cancer , 1995, Nature Genetics.
[126] G. Prins,et al. Regulation of proliferation and production of prostate-specific antigen in androgen-sensitive prostatic cancer cells, LNCaP, by dihydrotestosterone. , 1995, Endocrinology.
[127] L. Chung,et al. Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. , 1994, Cancer research.
[128] M. Gleave,et al. Derivation of androgen‐independent human LNCaP prostatic cancer cell sublines: Role of bone stromal cells , 1994, International journal of cancer.
[129] N. Hay,et al. Increased androgen receptor activity and altered c-myc expression in prostate cancer cells after long-term androgen deprivation. , 1994, Cancer research.
[130] H. Klocker,et al. Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone. , 1993, Molecular endocrinology.
[131] P. Vihko,et al. Growth factor regulation of gene expression in the human prostatic carcinoma cell line LNCaP. , 1993, Cancer research.
[132] T. H. van der Kwast,et al. Hormone-induced dissociation of the androgen receptor-heat-shock protein complex: use of a new monoclonal antibody to distinguish transformed from nontransformed receptors. , 1992, Biochemistry.
[133] T. H. van der Kwast,et al. Androgen receptors in endocrine‐therapy‐resistant human prostate cancer , 1991, International journal of cancer.
[134] Jean D. Wilson,et al. Androgen increases androgen receptor protein while decreasing receptor mRNA in LNCaP cells , 1991, Molecular and Cellular Endocrinology.
[135] G. Jenster,et al. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. , 1990, Biochemical and biophysical research communications.
[136] G. Murphy,et al. LNCaP model of human prostatic carcinoma. , 1983, Cancer research.
[137] C. Huggins,et al. Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate , 1941, CA: a cancer journal for clinicians.
[138] W. E. Gye,et al. CANCER RESEARCH , 1923, British medical journal.
[139] R. Vessella,et al. Molecular determinants of resistance to antiandrogen therapy , 2004, Nature Medicine.
[140] E. Latulippe,et al. Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. , 2004, The American journal of pathology.
[141] Hideo Araki,et al. Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome. , 2003, Cancer research.
[142] Desok Kim,et al. Androgen receptor expression and cellular proliferation during transition from androgen-dependent to recurrent growth after castration in the CWR22 prostate cancer xenograft. , 2002, The American journal of pathology.
[143] D. Horsfall,et al. Mutations at the boundary of the hinge and ligand binding domain of the androgen receptor confer increased transactivation function. , 2001, Molecular endocrinology.
[144] R. Agarwal,et al. Inhibitory effect of silibinin on ligand binding to erbB1 and associated mitogenic signaling, growth, and DNA synthesis in advanced human prostate carcinoma cells , 2001, Molecular carcinogenesis.
[145] R. Sutherland,et al. Altered expression of androgen receptor in the malignant epithelium and adjacent stroma is associated with early relapse in prostate cancer. , 2001, Cancer research.
[146] Taosheng Chen,et al. Elevation of cyclic adenosine 3',5'-monophosphate potentiates activation of mitogen-activated protein kinase by growth factors in LNCaP prostate cancer cells. , 1999, Cancer research.
[147] D. Peehl,et al. Induction of androgen receptor by 1alpha,25-dihydroxyvitamin D3 and 9-cis retinoic acid in LNCaP human prostate cancer cells. , 1999, Endocrinology.
[148] C. Young,et al. Resveratrol inhibits the expression and function of the androgen receptor in LNCaP prostate cancer cells. , 1999, Cancer research.
[149] G Bartsch,et al. Epidermal growth factor (EGF) receptor blockade inhibits the action of EGF, insulin-like growth factor I, and a protein kinase A activator on the mitogen-activated protein kinase pathway in prostate cancer cell lines. , 1999, Cancer research.
[150] G. Bubley,et al. High dose bicalutamide for androgen independent prostate cancer: effect of prior hormonal therapy. , 1998, The Journal of urology.
[151] H. Klocker,et al. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. , 1994, Cancer research.